• The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted marketing application submissions for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis
• This accepted submission is supported by a robust data package including three Phase 3 studies which demonstrate superiority of bimekizumab to placebo, Stelara® (ustekinumab) and Humira® (adalimumab) in achieving skin clearance at week 16

• Study met primary and secondary endpoints of significantly lowering the risk of developing a second primary generalized tonic-clonic seizure (PGTCS) during a 24-week treatment and a significantly higher rate of freedom from PGTCS during the treatment period compared with placebo 

UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer’s Disease

Bimekizumab Superior to Cosentyx® in Achieving Complete Psoriasis Skin Clearance

UCB completes the acquisition of Ra Pharmaceuticals – to deliver differentiated therapies to patients.

UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®